Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 146)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
2 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
3 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
4 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
5 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
6 |
|
Macitentan |
Approved |
Phase 2, Phase 3 |
|
441798-33-0 |
16004692 |
Synonyms:
ACT 064992
ACT064992
ACT-064992
ACT-064992|Opsumit®
|
MACITENTAN
Macitentán
MACITENTANUM
OPSUMIT
|
|
7 |
|
Sildenafil |
Approved, Investigational |
Phase 3 |
|
139755-83-2, 171599-83-0 |
5212 135398744 |
Synonyms:
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulphonyl)-4-methylpiperazine
1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
1-{[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL}-4-METHYLPIPERAZINE
5-[2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL]-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE
5-[2-ETHOXY-5-(4-METHYL-PIPERAZINE-1-SULFONYL)-PHENYL]-1-METHYL-3-PROPYL-1,6-DIHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE
Acetildenafil
Aphrodil
Caverta
Citrate, sildenafil
Desmethyl sildenafil
Desmethylsildenafil
HIP0908
HIP-0908
Homosildenafil
Hydroxyhomosildenafil
Lactate, sildenafil
NCX 911
|
NCX-911
NIPATRA
Nitrate, sildenafil
Revatio
Sildenafil
Sildenafil citrate
Sildenafil lactate
Sildenafil nitrate
Sildenafil Viagra
Sildenafil, desmethyl
Sildenafilo
UK-92480
UK-9248010
UK-92480-10
Viagra
Viagra®
VIZARSIN
|
|
8 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
9 |
|
Tadalafil |
Approved, Investigational |
Phase 3 |
|
171596-29-5 |
110635 |
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
351, IC
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
Adcirca
Adcirca®|Cialis®|IC-351|IC351
Cialis
|
IC351
IC-351
ICOS 351
Tadalafil
Tadalafilo
Tadanafil
Zalutia
|
|
10 |
|
Acetylcholine |
Approved, Investigational |
Phase 3 |
|
51-84-3 |
187 |
Synonyms:
[2-(ACETYLOXY)ETHYL]TRIMETHYLAZANIUM
2-(Acetyloxy)-N,N,N-trimethylethanaminium
2-ACETOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AZANIUM
Acetilcolina cusi
Acetyl choline ion
Acetylcholine
Acetylcholine bromide
Acetylcholine cation
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
ACETYLCHOLINE, ACH
Acetylcholinium: acetyl-choline
|
ACh
ACh|E1001|O-acetylcholine
Alcon brand OF acetylcholine chloride
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
E1001
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
11 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
12 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 3 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
13 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 3 |
|
52-21-1 |
|
Synonyms:
ECONOPRED
FLO-PRED
METICORTELONE
NSC-10966
OMNIPRED
PRED FORTE
|
PRED FTE
PRED MILD
PREDNISOLONE 21-ACETATE
PREDNISOLONE ACETATE
STERANE
ULTRACORTENOL
|
|
14 |
|
Prednisolone |
Approved, Vet_approved |
Phase 3 |
|
50-24-8 |
4894 5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11Î’)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Codelcortone
Co-Hydeltra
Cordrol
CORTALONE
Cotogesic
Cotolone
Decaprednil
Decortin H
DEKOTIL
Delcortol
Delta F
Delta(1)-Dehydrocortisol
Delta(1)-Dehydrohydrocortisone
Delta(1)-Hydrocortisone
DELTA.1-CORTISOL
DELTA.1-Cortisol|Orapred®|Pediapred®
Delta-Cortef
Deltacortenol
DELTACORTRIL
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
Deltahydrocortisone
DELTALONE
Deltasolone
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
DESOWEN
Dexa-Cortidelt Hostacortin H
Di adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Dicortol
DILACORT
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
FERNISOLONE-P
Flamasone
Hostacortin H
HYDELTRA
Hydeltrasol
HYDELTRA-TBA
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
IMS904
Inflamase Forte
Inflamase Mild
I-Pred
Key-Pred
Klismacort
Lentosone
Lite Pred
Medrol
|
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
METICORTELONE
METI-DERM
Metreton
M-Predrol
NEO-DELTA-CORTEF
Nisolone
Nor-Pred T.B.A.
NSC-9120
NSC-9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
ORAPRED
Panafcortelone
Paracortol
Paracotol
PEDIAPRED
PEVANTI
POLY-PRED
PRDL
Precortalon
Precortancyl
Precortilon
PRECORTISYL
PRECORTISYL FTE
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
PREDL
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone acetate
Prednisolone sodium phosphate
Prednisolone tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
PRELONE
Prenolone
Rolisone
SCHERIPROCT
Scherisolon
SERVISONE
Solone
Steran
STERANE
Sterolone
Supercortisol
TRIDESILON
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
VERDESO
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
15 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 3 |
|
2921-57-5 |
1875 |
Synonyms:
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinic acid
|
Methylprednisolone hydrogen succinate
Methylprednisolone succinate
|
|
16 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 3 |
|
83-43-2 |
4159 6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
6 Methylprednisolone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
Artisone-Wyeth
Besonia
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
Dopomedrol
Esametone
Firmacort
J3.872E
Lemod
Medesone
Medixon
Medlone 21
Medrate
Medric acid
Medrol
Medrol Adt Pak
Medrol Dosepak
Medrol®|U-67590A
Medrone
Mesopren
|
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
Nirypan
Noretona
NSC-19987
Predni N Tablinen
Promacortine
Reactenol
Sieropresol
Solomet
SOLU-MEDROL
Summicort
Suprametil
U-67590A
Urbason
Urbasone
Wyacort
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
17 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
18 |
|
Mycophenolic acid |
Approved, Investigational |
Phase 3 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
68618
Acid, mycophenolic
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Cellcept
ERL080
ERL-080
ERL-080|Myfortic® (mycophenolate sodium)
Melbex
Micofenolico acido
Mofetil hydrochloride, mycophenolate
Mofetil, mycophenolate
|
Mycophenoic acid
Mycophenolate
Mycophenolate mofetil
Mycophenolate mofetil hydrochloride
Mycophenolate sodium
Mycophenolate, sodium
MYCOPHENOLIC ACID
Mycophenolic acid morpholinoethyl ester
Mycophenolsaeure
Mycophenolsäure
Myfortic
NSC-129185
RS-61443 [AS MOFETIL]
Sodium mycophenolate
|
|
19 |
|
Coenzyme M |
Approved, Investigational |
Phase 3 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Î’-mercaptoethanesulfonate
Î’-mercaptoethanesulfonic acid
Î’-mercaptoethanesulphonate
Î’-mercaptoethanesulphonic acid
|
|
20 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
21 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 3 |
|
2920-86-7 |
4897 |
Synonyms:
(+)-prednisolone hemisuccinate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethoxy)-4-oxobutanoate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
PREDNISOLONE HEMISUCCINATE
Prednisolone hemisuccinic acid
Prednisolone hydrogen succinate
PREDNISOLONE SUCCINATE
|
|
22 |
|
Endothelin A Receptor Antagonists |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
24 |
|
Anesthetics |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
26 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
27 |
|
Anticoagulants |
|
Phase 3 |
|
|
|
28 |
|
Phosphodiesterase Inhibitors |
|
Phase 3 |
|
|
|
29 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 3 |
|
|
|
30 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
31 |
|
Citrate |
|
Phase 3 |
|
|
|
32 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
33 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
34 |
|
Insulin, Globin Zinc |
|
Phase 3 |
|
|
|
35 |
|
Insulin |
|
Phase 3 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
36 |
|
abobotulinumtoxinA |
|
Phase 3 |
|
|
|
Synonyms:
ABOBOTULINUMTOXINA
BONT/A
BONTOXILYSIN A
BOTOX
BOTULINUM TOXIN TYPE A
|
BOTULINUM TOXINS, TYPE A
BOTULOTOXIN A
BTX-A
ONABOTULINUMTOXINA
|
|
37 |
|
Botulinum Toxins, Type A |
|
Phase 3 |
|
|
|
38 |
|
Botulinum Toxins |
|
Phase 3 |
|
|
|
39 |
|
Cholinergic Agents |
|
Phase 3 |
|
|
|
40 |
|
Chelating Agents |
|
Phase 3 |
|
|
|
41 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
42 |
|
Methylprednisolone Acetate |
|
Phase 3 |
|
|
584547 |
Synonyms:
Acetyl methylprednisolone
Acetyl-methylprednisolone
DEPMEDALONE
Depo medrol
Depo medrone
Depo-medrol
Depo-medrone
|
MEDROL ACETATE
Methylprednisolone 21 acetate
METHYLPREDNISOLONE ACETATE
Methylprednisolone acetate, (11beta,16alpha)-isomer
Methylprednisolone acetate, (11beta,16beta)-isomer
Methylprednisolone acetic acid
Methylprednisolone-21-acetate
|
|
43 |
|
Antilymphocyte Serum |
|
Phase 3 |
|
|
|
44 |
|
Thymoglobulin |
|
Phase 3 |
|
|
|
45 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
46 |
|
Rituximab |
Approved |
Phase 2 |
|
174722-31-7 |
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
47 |
|
Abatacept |
Approved |
Phase 1, Phase 2 |
|
332348-12-6 |
|
Synonyms:
ABATACEPT
ABATACEPT (GENETICAL RECOMBINATION)
Abatacept recombinant
BMS-188667
BMS-188667|CTLA4-IgG4m|Orencia®|RG-1046|RG-2077
CTLA4IG
CTLA4-IG
|
CTLA4IGG4M
CTLA4-IGG4M
ORENCIA
ORENCIA CLICKJECT
RG-1046
RG-2077
|
|
48 |
|
Epoprostenol |
Approved |
Phase 2 |
|
61849-14-7, 35121-78-9 |
5282411 |
Synonyms:
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9Α-epoxy-11α,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9Α-epoxy-11α,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9Α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9Α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
ACT-385781A
Epoprostanol
|
Epoprostenol
EPOPROSTENOL SODIUM
Epoprostenol sodium salt, (5Z,9alpha,11alpha,13E,15S)-isomer
EPOPROSTENOLSODIUM
FLOLAN
PGI2
PG-I2
PGX
Prostacyclin
PROSTACYCLIN SODIUM SALT
prostacyclin|prostacyclin I2|prostaglandin I2|vasocyclin
Prostacycline
Prostaglandin I(2)
PROSTAGLANDIN I2
Prostaglandin X
U-53217
U-53217A
Vasocyclin
VELETRI
|
|
49 |
|
Treprostinil |
Approved, Investigational |
Phase 2 |
|
81846-19-7 |
6918140 |
Synonyms:
((1R,2R,3AS,9as)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
(1R,2R,3AS,9AS)-[[2,3,3A,4,9,9A-HEXAHYDRO-2-HYDROXY- 1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[F]INDEN-5-YL] OXY]ACETIC ACID
[[(1R,2R,3AS,9AS)-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-2,3,3A,4,9,9A-HEXAHYDRO-1H-CYCLOPENTA[B]NAPHTALEN-5-YL]OXY]ACETIC ACID
15AU81
15-AU-81
LRX-15
LRX-15|Remodulin®|Tyvaso®
Orenitram
Remodulin
Trepostinil sodium
Treprostinil
Tréprostinil
|
Treprostinil diethanolamine
Treprostinil diolamin
Treprostinil diolamine
Treprostinil sodium
Treprostinilo
Treprostinilum
TRESPROSTINIL
TYVASO
UNIPROST
UT-15
UT-15C
|
|
50 |
|
Dasatinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
Interventional clinical trials:
(show top 50)
(show all 117)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Safety and Efficacy of Vaccination Against Influenza in Patients With Scleroderma |
Unknown status |
NCT01002508 |
Phase 4 |
|
2 |
The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial |
Completed |
NCT03630198 |
Phase 4 |
Corticosteroid with lidocaine;Corticosteroid with normal saline |
3 |
A Phase IV, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in Patients With Fibrotic and Atrophic Cutaneous Lesions in Scleroderma Diseases |
Terminated |
NCT03388255 |
Phase 4 |
Polydeoxyribonucleotides |
4 |
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated Interstitial Lung DiseasE and Pulmonary Hypertension (PH): The CRuSADE PH Study |
Unknown status |
NCT03726398 |
Phase 2, Phase 3 |
Opsumit 10 Mg Tablet |
5 |
Evaluation of the Efficacy and Safety of the Imiquimod 5% Topical Cream in Plaque Morphea: A Prospective, Multiple Baseline, Open Label Pilot Study |
Completed |
NCT00147771 |
Phase 3 |
Imiquimod 5% cream |
6 |
Effectiveness and Safety of Lidocaine for Scleroderma. Randomized Double-Blind Clinical Trial |
Completed |
NCT00740285 |
Phase 2, Phase 3 |
Lidocaine 2% without vessel constrictor |
7 |
High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) |
Completed |
NCT00501995 |
Phase 3 |
IV Cyclophosphamide |
8 |
Cyclophosphamide Versus Placebo in Scleroderma Lung Study |
Completed |
NCT00004563 |
Phase 3 |
Cyclophosphamide;Placebo |
9 |
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study |
Completed |
NCT01117298 |
Phase 3 |
Tadalafil;Placebo |
10 |
A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome |
Completed |
NCT02165111 |
Phase 3 |
Onabotulinumtoxin A;sterile saline solution |
11 |
Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial |
Completed |
NCT01347008 |
Phase 3 |
Sildenafil citrate;Placebo (Sugar pill) |
12 |
Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study |
Completed |
NCT01295736 |
Phase 3 |
Sildenafil;placebo |
13 |
Upfront Autologous Hematopoietic Stem Cell Transplantation Versus Immunosuppressive Medication in Early Diffuse Cutaneous Systemic Sclerosis: an International Multicentre, Open-label, Randomized Con-trolled Trial |
Recruiting |
NCT04464434 |
Phase 3 |
|
14 |
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells - A Randomized, Double-Blind, Placebo-Controlled Study - The STAR-II Trial |
Not yet recruiting |
NCT05148598 |
Phase 3 |
|
15 |
Evaluation of the Efficacy and Safety of Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study |
Withdrawn |
NCT00230373 |
Phase 3 |
imiquimod 5% cream (Aldara) |
16 |
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea |
Completed |
NCT03351114 |
Phase 2 |
Crisaborole |
17 |
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy |
Completed |
NCT00936546 |
Phase 2 |
Rituximab |
18 |
Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement. |
Completed |
NCT00479934 |
Phase 2 |
imatinib mesylate |
19 |
The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study |
Completed |
NCT00129428 |
Phase 1, Phase 2 |
|
20 |
A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma |
Completed |
NCT02047708 |
Phase 2 |
Zibotentan |
21 |
A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis |
Completed |
NCT00442611 |
Phase 1, Phase 2 |
Abatacept;Placebo |
22 |
DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study |
Completed |
NCT00775463 |
Phase 2 |
treprostinil diethanolamine;placebo |
23 |
An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis |
Completed |
NCT00764309 |
Phase 1, Phase 2 |
dasatinib |
24 |
Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma |
Completed |
NCT00005675 |
Phase 2 |
Oral bovine type I collagen;Placebo |
25 |
Psychosocial Interventions for Scleroderma |
Completed |
NCT00007267 |
Phase 2 |
|
26 |
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II) |
Completed |
NCT00883129 |
Phase 2 |
Mycophenolate mofetil;Cyclophosphamide;Placebo |
27 |
Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial |
Completed |
NCT00278525 |
Phase 2 |
standard of care |
28 |
Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers. |
Completed |
NCT02801305 |
Phase 2 |
Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline |
29 |
Effect of Bosentan in the Course of Scleroderma Renal Crisis |
Completed |
NCT01241383 |
Phase 2 |
Bosentan |
30 |
Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial |
Completed |
NCT01538719 |
Phase 1, Phase 2 |
Rilonacept |
31 |
A Multi-center Randomized, Double Blind, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Riociguat in Scleroderma - Associated Digital Ulcers |
Completed |
NCT02915835 |
Phase 2 |
Riociguat;Placebo |
32 |
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells |
Completed |
NCT02213705 |
Phase 1, Phase 2 |
|
33 |
A Randomized, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma |
Recruiting |
NCT04200755 |
Phase 2 |
Dupilumab 300Mg Solution for Injection |
34 |
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH) |
Recruiting |
NCT02682511 |
Phase 2 |
Oral Ifetroban;Oral Placebo |
35 |
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma |
Recruiting |
NCT04797286 |
Phase 2 |
Sildenafil |
36 |
A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease |
Recruiting |
NCT04837131 |
Phase 2 |
Ixazomib |
37 |
A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis |
Active, not recruiting |
NCT04647890 |
Phase 2 |
FT011;Placebo |
38 |
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease |
Active, not recruiting |
NCT03221257 |
Phase 2 |
Pirfenidone (PFD);Placebo (Plac);Mycophenolate Mofetil (MMF) |
39 |
A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) |
Terminated |
NCT03740724 |
Phase 1, Phase 2 |
veledimex |
40 |
Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension |
Terminated |
NCT00377455 |
Phase 2 |
Bosentan;Placebo |
41 |
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease |
Terminated |
NCT01559129 |
Phase 2 |
Pomalidomide (CC-4047);Placebo |
42 |
A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma |
Terminated |
NCT01545427 |
Phase 2 |
Imatinib mesylate |
43 |
A Pilot Study to Assess the Safety and Efficacy of Sarilumab in Halting Progression of Morphea |
Withdrawn |
NCT03679845 |
Phase 1, Phase 2 |
Sarilumab |
44 |
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma |
Completed |
NCT02426229 |
Phase 1 |
dabigatran etexilate |
45 |
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma |
Completed |
NCT00946699 |
Phase 1 |
|
46 |
A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma |
Completed |
NCT00930683 |
Phase 1 |
MEDI-546 |
47 |
Comparative Effectiveness Trial of Topical Calcipotriene, Clobetasol, and Tacrolimus in the Treatment of Pediatric Plaque Morphea |
Withdrawn |
NCT02680717 |
Phase 1 |
Clobetasol;Calcipotriene;Tacrolimus |
48 |
Fractional Carbon Dioxide Laser Versus UVA1 Phototherapy for Treatment of Localized Scleroderma: A Clinical & Immunohistochemical Comparative Study |
Unknown status |
NCT02002897 |
|
|
49 |
Adult-onset Generalized Morphea : A Retrospective Multicenter Study |
Unknown status |
NCT04264728 |
|
|
50 |
Pilot Study of descriPtion of cicatriSation Rates of Digital Ulcers in Systemic scleroDerma |
Unknown status |
NCT04319120 |
|
|
|